Skip to main content
KREDKRED
476060KOSDAQ

Onconic Therapeutics

14,870
-640 (-4.13%)

Price chart

  • MA5
  • MA20
  • MA60

Adjusted prices rescale past bars with coefficients taken from the base prices the exchange itself published, correcting for corporate actions such as stock splits and reverse splits. Cash dividends are not reflected, and the risk measures on this page never use these adjusted figures.

Market capitalizationKRW 1T

Each day's close multiplied by the listed share count of this share class alone, sampled weekly. It is the figure for this issue only, not a combined total across common and preferred shares.

Overview

Summary

Onconic Therapeutics is a company established on May 7, 2020. It is listed on the KOSDAQ market.

The company researches and develops small molecule based innovative drugs for acid related digestive diseases and oncology. Its main products include Jaqubo, a P-CAB treatment for erosive gastroesophageal reflux disease and gastric ulcers, and Nesuparib, a dual target anticancer agent.

Business overview as filed

온코닉테라퓨틱스㈜ (이하 당사)는 미충족 의료 수요(Unmet medical needs)가 큰 위산 유발 소화기질환 및 항암 분야의 글로벌 혁신 신약을 연구개발 하는 회사입니다. 당사는 바이오신약 대비 개발 비용 및 상업화 비용이 상대적으로 저렴하여, 질병으로 고통받고 있는 환자들에게 합리적인 비용의 신치료신약을 공급할 수 있는 저분자 화합물(Small molecule) 기반의 신약을 연구 개발하는데 집중하고 있으며, 시장 내 미충족 의료 수요(Unmet medical needs)가 큰 소화기질환 및 합성치사 항암 분야에서 저분자 합성신약과 대한 독보적인 기술 및 연구개발 역량을 가지고 있습니다.

- 당사의 위산 유발 소화기질환 치료 신약인 P-CAB기전의 "자큐보정" 은 국산신약 37호로서 미란성 위식도역류질환과 위궤양 치료제로 신약품목허가를 완료하였습니다 위산 유발 소화기질환은 한국을 비롯하여 전 세계에 많은 환자가 있는 가장 흔한 소화기계 질환으로, 전세계적으로 약 20조원 이상되는 시장성이 매우 큰 질환입니다. 생명을 위협하는 질환은 아니지만, 질환으로 고통받는 환자가 많고, 심한 증상일 경우 심장마비와 유사한 가슴 통증 등으로 삶의 질이 현저히 떨어지는 질환으로 그 치료제에 대한 시장의 Unmet medical needs(미충족 의료 수요)가 큰 질환입니다.

기존 일시적인 증상억제 제산제 및 H2Blocker 등을 거쳐 현재 가장 널리 사용되고 있는 치료제는 PPI (Proton pump inhibitor)입니다. PPI는 1)전구약물 (prodrug)이라는 기전적인 한계로 인해 약효 발현이 느리고, 2)식사 후 투약 시 위산분비 저해 효능이 감소함으로 아침 식전에 투약해야 하고, 3)약효의 지속력의 한계로 야간 산분비 억제가 어려운 점, 4)특정 약물과의 상호작용이 있다는 단점등을 보유하고 있습니다. 이에 따라 새로운 기전의 치료제 필요성이 지속적으로 요구되어 왔습니다.

이러한 의료현장의 미충족의료수요를 해결하기 위하여 개발한 "자큐보정"은 P-CAB(Potassium-Competitive Acid Blocker)기전의 신약물질로 기존 PPI 약물과는 달리1) 투약 후 즉시 양성자 펌프를 완전저해 (Full inhibition) 함으로 1시간내에 신속히 효능 발현이 됩니다.

2) 휴지 상태의 펌프까지도 저해하여 약효능이 매우 높습니다.

3)산분비의 활성이 필요하지 않아 식전후 구분없이 투약이 가능하여 환자의 복약편의성이 높습니다.

4)장시간 위산억제 효능을 유지하여 야간 수면을 방해하는 야간 위산분비도 효과적으로 억제할 수 있습니다.

이러한 신약으로서의 장점을 통해 PPI가 기존 H2Blocker등을 대신하여 치료제로 부상, 시장을 대체한 것과 같이, 자큐보정은 기존 PPI약물을 대체하는 새로운 치료제로 높은 성공 가능성을 가지고 있습니다. 또한 높은 복약 순응도 및 높은 치료효과 및 지속력으로 기존 PPI로 치료가 불가능하였던 중증환자군들에서도 효과를 기대할 수 있습니다.

또한 당사는 합성치사 기전의 차세대 표적항암제인 PARP/Tankyrase 동시저해 이중표적항암제 Nesuparib과 First-in class의 항암신약후보물질의 연구를 수행하고 있습니다.

암생태계의 복잡성으로 인해 기존 표적항암제들은 암 발병인자(Oncogene)의 단일 직접 저해로는 치료제 개발(적응증 확대) 및 항암효과 극대화에 있어서 많은 한계가 있었습니다. 이러한 단일 (직접) 타겟 표적항암제들의 제한성을 극복하고자 AstraZeneca를 포함한 저분자 합성화합물 기반 기업들은 암생태계의 합성치사를 활용하여 암세포가 사멸될 수 있도록 조절하는 연구를 진행하였으며, 암세포의 합성치사를 유발하여 암세포를 사멸시키는DDR(DNA Damage Repair)저해제 계통의 PARP 저해제가 등장, 항암신약으로 허가를 받게 되었습니다.

당사는 저분자 화합물 기반의 DDR저해 방식의 합성치사유도 항암제 연구 개발을 통해, 시장에서 성공한 PARP기전을 기반으로, 기존 단일 저해 기전을 넘어서는 이중(타겟)저해 기술 합성치사 항암제와 새로운 DDR타겟둘에 대한 연구개발에 집중 하고 있습니다. 합성치사 항암분야의 차세대 신약의 개발에 역량을 집중하고 있습니다.

Company overview

가. 연결대상 종속회사 현황(요약)

사업보고서 제출일 현재 해당사항이 없습니다.

1-1. 연결대상회사의 변동내용

나. 회사의 법적ㆍ사업적 명칭당사의 한글 명칭은 "온코닉테라퓨틱스 주식회사"이며, 영문으로는 "Onconic Therapeutics Inc." 라 표기합니다.

다. 설립일자당사는 2020년 5월 7일에 설립되었습니다.

라. 본사의 주소, 전화번호, 홈페이지

마. 회사사업 영위의 근거가 되는 법률

사업보고서 제출일 현재 해당사항이 없습니다.

바. 중소기업 등 해당 여부

사. 주요 사업의 내용 및 향후 추진하려는 신규사업당사는 Unmet medical needs가 큰 위산 유발 소화기 질환(Acid-related Disease) 및 항암 분야의 글로벌 혁신 신약을 연구개발 하는 회사입니다. 당사는 바이오 신약 대비 개발 비용 및 상업화 비용이 상대적으로 저렴하여, 질병으로 고통받고 있는 환자들에게 합리적인 가격의 신치료신약을 공급할 수 있는, 저분자 화합물(Small molecule) 기반의 신약을 연구 개발하는데 집중하고 있습니다.

아. 신용평가에 관한 사항사업보고서 제출일 현재 해당사항이 없습니다.

자. 회사의 주권상장(또는 등록ㆍ지정) 및 특례상장에 관한 사항

Transcribed verbatim from the sentences the filer wrote in the fiscal 2025 business report (received 2026.03.13), tables and figures omitted.

  • The summary is written separately from the filed text and is not the filer's wording, so it may phrase things differently from or omit parts of the original, which is shown alongside for checking.
  • The company introduction reproduces the sentences the filer wrote in its business report, with tables, figures and the sentences that point to other sections of the report omitted, and the accuracy of their content has not been separately verified.

VaR

6.74%
[4.18%, 11.02%] · As of 2026-10-02
VaR by window

The headline's measure for each of the three windows on one scale, the dot being the estimate and the bar its interval. The windows are nested and share their observations, so the three readings are not three independent measurements. The selected window is highlighted.

Daily return distribution

The issue's daily returns over the chosen window counted into equal-width bins. The vertical lines mark the VaR and cVaR above on the loss side. The published VaR sample applies exclusion rules for halts and first sessions that this raw daily series does not, so the bars and the marks can differ slightly at the edges.

Drawdown

Deepest drawdown 63.8% (2026-07-30). How far below its previous peak the issue stood each day over the chosen window, a description of the path already travelled.

If these numbers are unfamiliarThere is a guide that walks through VaR, cVaR and annualized volatility in plain language.Read the guide

Characteristic line

0.79
Beta [0.63, 0.96] · KOSDAQ150 · As of 2026-10-08
Intercept
+0.267%[-0.480%, +1.015%]
R squared
0.17
Observations
252
Trading-time corrected beta
0.79[0.45, 1.13]
252-day rolling beta

A 252-day window rolled one day at a time over the longest daily span of the characteristic line. It shows when the beta against the KOSDAQ150 and the annualized volatility of the issue's excess return rose and fell, and unlike the headline figures above it carries no interval.

252-day rolling annualized volatility

Each point is one period's index excess return and issue excess return, and the line is the regression fitted to those points. The risk-free rate is the certificate of deposit rate.

Financials

202320242025TTM
RevenueNot applicableNot applicableNot applicableNot applicable
Operating incomeKRW 100M22-48126173
Operating income growth%—-315.06——
Net incomeKRW 100M17-81158243
Net income growth%—-581.00——
Attributable to ownersNot applicableNot applicableNot applicableNot applicable
Attributable to minoritiesNot applicableNot applicableNot applicableNot applicable
Operating marginNot applicableNot applicableNot applicableNot applicable
Net marginNot applicableNot applicableNot applicableNot applicable
ROENot applicableNot applicableNot applicableNot applicable
ROA%4.48-13.2920.8526.08
Debt ratio%-290.708.745.098.40
Current ratio%53.951,094.011,762.181,139.10
Quick ratioNot applicableNot applicableNot applicableNot applicable
Reserve ratio%-826.07894.07221.43277.45
Free cash flowKRW 100M30-80111—
OCF conversion%246.37—72.19—
EPSKRW291-990359—
PERx——54.46—
BPSNot applicableNot applicableNot applicableNot applicable
PBRNot applicableNot applicableNot applicableNot applicable
Dividend per shareNot applicableNot applicableNot applicableNot applicable

Separate basis

Cash flow by activityKRW 100M

Balance sheet compositionKRW 100M

Debt ratio%

The left bar splits assets into current and non-current and the right bar splits the financing of those assets into liabilities and equity, so the two bars stand at the same height.

Free cash flow breakdownKRW 100M

Free cash flow is cash from operating activities less spending on property, plant and equipment, and all three bars keep the sign as filed.

Financial statements

Balance sheet

202320242025
375609757
5724937
-197560720

Income statement

202320242025
Not applicableNot applicableNot applicable
22-48126
7-99137
17-81158
Basic earnings per shareKRW291-990*359
Diluted earnings per shareKRW291-990*348
17-81157

Cash flow statement

202320242025
Net incomefrom the income statement17-81158
Total adjustments to operating cash flowcomputed253-44
41-78114
-10-1-62
-2196-5
Cash at beginning of periodKRW 100M273301430
301430470
Net change in cash and cash equivalentsKRW 100MNot applicableNot applicableNot applicable

In the latest fiscal year cash generated by operations covered both investing outflows and financing outflows.

A year whose own filing is absent is filled from the restated comparative in the following filing, and is marked as such. Operating indicators outside the statements, such as order backlogs, and audit opinions are not covered here, and per-share figures follow the filed values without retroactive adjustment for share splits.

Transcribed verbatim from the sentences the filer wrote in the fiscal {year} business report (received {date}), with tables, figures and cross-references to other sections omitted.

The newest annual filing shown was received on 2026.03.13.

Audit opinion

Fiscal yearOpinionAuditorFiscal year end
2025적정의견Term 6한영회계법인2025-12-31
2024적정의견Term 5한영회계법인2025-12-31
2023적정의견Term 4대주회계법인2025-12-31

The auditor's name and the opinion are transcribed verbatim from the filed audit report, and the wording follows the filer. A fiscal year shown twice means the filing carried two entries that the source does not distinguish.

Korean audit opinions come in four kinds, where an unqualified opinion (적정) finds the statements fairly presented, a qualified opinion (한정) does so except for a stated matter, an adverse opinion (부적정) finds them not fairly presented, and a disclaimer of opinion (의견거절) means the auditor could not obtain enough evidence to form a view.

Valuation

Valuation multiplesx

PER and PBR divide each period's closing price by the per-share figure filed for that same period, and a loss period is left blank. The quarterly view is a multiple of quarterly EPS.

Valuation models

Five models priced under one set of assumptions, set beside the current price, with how each has moved by fiscal year.

Assumptions

Risk-free rate10-year treasury yield · 2026-10-084.40%
BetaDaily 1Y0.79
%
%
Cost of equity8.35%
Weighted average cost of capital—
Initial growth2.0%
Effective tax rate0.0%
Base fiscal year2025
Current priceKRW14,870

The risk premium and the terminal growth rate are adjustable assumptions, and the rest follow from the data and the formulas.

ModelModel priceKRWVersus current price
Gordon growth modelNo dividend
Dividend discount model DDMNo dividend
Discounted cash flow FCFFNo borrowing line filed
Discounted cash flow FCFE4,003-73.1%
Residual income model RIMNo book value or return on equity
The table prices the newest fiscal year's accounts at today's treasury yield and the current price.

Dividend and residual income familyKRW

Discounted cash flow familyKRW

Each fiscal year's figures use that year's accounts and the treasury yield at its period end, with beta held at its current value, and splits or par changes are restated to the current share basis.

How the figures are calculated

Each model's formula is shown in symbols and then with this issue's own numbers substituted, step by step. Changing a value in the assumptions panel changes the numbers here too. Firm-level amounts are in hundred million won and per-share values in won.

Cost of equity

r=rf+β×ERPr = r_f + \beta \times \mathit{ERP}

r = 4.40% + 0.79 × 5.00% = 8.35%

Initial growth

g1=max⁡{ROE×(1−payout), 0},gt=g1+(gT−g1) t−1N−1g_1 = \max\{\mathit{ROE} \times (1 - \text{payout}),\,0\},\qquad g_t = g_1 + (g_T - g_1)\,\frac{t-1}{N-1}

g_1 = g_T = 2.00%

Discounted cash flow FCFE

FCFE0=CFO−CapEx+ΔD,P0=1Shares[∑t=1NFCFEt(1+r)t+FCFEN(1+gT)(r−gT) (1+r)N],FCFEt=FCFEt−1(1+gt)\mathit{FCFE}_0 = \mathit{CFO} - \mathit{CapEx} + \Delta D,\qquad P_0 = \frac{1}{\text{Shares}}\left[\sum_{t=1}^{N} \frac{\mathit{FCFE}_t}{(1+r)^t} + \frac{\mathit{FCFE}_N (1+g_T)}{(r - g_T)\,(1+r)^N}\right],\qquad \mathit{FCFE}_t = \mathit{FCFE}_{t-1}(1+g_t)

Base-year cash flow FCFE

FCFE_0 = 114.0 − 3.0 + 0.0 (net borrowing) = 110.9 KRW hundred million

YearGrowthCash flow KRW hundred millionDiscount factorPresent value KRW hundred million
12.00%113.10.9229104.4
22.00%115.40.851898.3
32.00%117.70.786192.5
42.00%120.10.725587.1
52.00%122.50.669682.0
Terminal value2.00%1,966.40.66961,316.7
Total1,781.0

P_0 = 1,781.0 KRW hundred million ÷ 44,489,866 (shares) = 4,003 KRW

The cost of equity is the risk-free rate plus beta times the equity risk premium. Initial growth is the newest fiscal year's return on equity times its retention ratio, floored at zero, and falls by equal steps from that value in the first year to the terminal rate in the fifth. Only the Gordon model grows at the terminal rate from the start. Discounted cash flow starts from operating cash flow less capital expenditure, where FCFF adds after-tax interest paid and discounts at the weighted average cost of capital, and FCFE adds net borrowing and discounts at the cost of equity. The residual income model adds to book value per share the present value of earnings above the equity charge.

Other issues on the same market

Neighbours in the market capitalisation order.

See the full KOSDAQ list